A new deal giving Celgene Corp. strategically important rights to a PD-1 inhibitor developed by Beijing-based Beigene Ltd. will tightly bond the companies' fortunes in both the U.S. and China, putting Celgene in charge of development and commercialization of a key Beigene asset, while Beigene takes charge of selling Celgene's top products in China and advancing new ones.